We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sorrento Therapeutics (SRNE) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Sorrento Therapeutics (SRNE - Free Report) closed at $6.68, marking a +1.52% move from the previous day. This change outpaced the S&P 500's 0.34% loss on the day. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.73%.
Heading into today, shares of the biopharmaceutical company had gained 39.11% over the past month, outpacing the Medical sector's gain of 5.8% and the S&P 500's gain of 5.71% in that time.
Investors will be hoping for strength from SRNE as it approaches its next earnings release. The company is expected to report EPS of -$0.22, up 43.59% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8 million, up 23.46% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.86 per share and revenue of $42.36 million, which would represent changes of +59.43% and +34.77%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for SRNE. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 15.56% higher. SRNE currently has a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sorrento Therapeutics (SRNE) Gains As Market Dips: What You Should Know
In the latest trading session, Sorrento Therapeutics (SRNE - Free Report) closed at $6.68, marking a +1.52% move from the previous day. This change outpaced the S&P 500's 0.34% loss on the day. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.73%.
Heading into today, shares of the biopharmaceutical company had gained 39.11% over the past month, outpacing the Medical sector's gain of 5.8% and the S&P 500's gain of 5.71% in that time.
Investors will be hoping for strength from SRNE as it approaches its next earnings release. The company is expected to report EPS of -$0.22, up 43.59% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8 million, up 23.46% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.86 per share and revenue of $42.36 million, which would represent changes of +59.43% and +34.77%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for SRNE. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 15.56% higher. SRNE currently has a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.